GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Net Income Including Noncontrolling Interests

Mind Medicine (Mind Medicine) Net Income Including Noncontrolling Interests : $-125.32 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Mind Medicine's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was $-54.40 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was $-125.32 Mil.

Mind Medicine Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Mind Medicine's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Net Income Including Noncontrolling Interests Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
-33.94 -93.04 -56.80 -95.73

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.82 -29.13 -17.92 -23.86 -54.40

Mind Medicine Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-125.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mind Medicine Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
TSX:EPRX XCNQ:DTC TSX:ONC TSXV:NGEN TSX:BCT XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MNMD:USA MMQ:Germany MMED:Canada
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Website
https://www.mindmed.co
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.